{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:16:55Z","timestamp":1789676215606,"version":"4.0.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.urolonc.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:07:31Z","timestamp":1778584051000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Contemporary management of adrenocortical carcinoma: A narrative review"],"prefix":"10.1016","author":[{"given":"Ankit","family":"Misra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Phadte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanthapriya","family":"Subramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Dhanawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyamvada","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendra","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Lila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.urolonc.2026.04.010_bib0001","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993","volume":"49","author":"Kerkhofs","year":"2013","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.010_bib0002","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.010_bib0003","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1210\/jc.2016-2894","article-title":"Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma","volume":"102","author":"Berruti","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2026.04.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112488","article-title":"Current advances in prognostic and diagnostic biomarkers for solid cancers: detection techniques and future challenges","volume":"146","author":"Pal","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17446651.2024.2431748","article-title":"Adrenocortical tumors and hereditary syndromes","volume":"20","author":"Jeyaraman","year":"2025","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.010_bib0006","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","article-title":"Adrenocortical carcinoma: a practical guide for clinicians","volume":"13","author":"Fassnacht","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.010_bib0007","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1210\/clinem\/dgad199","article-title":"New findings on presentation and outcome of patients with adrenocortical cancer: results from a National Cohort Study","volume":"108","author":"Puglisi","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.010_bib0008","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/jc.2005-2730","article-title":"Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients","volume":"91","author":"Abiven","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.010_bib0009","doi-asserted-by":"crossref","first-page":"luad073","DOI":"10.1210\/jcemcr\/luad073","article-title":"Dual aldosterone- and cortisol-secreting adrenal cortical carcinoma: pre- and perioperative evaluation and management","volume":"1","author":"Rosenberg","year":"2023","journal-title":"JCEM Case Rep"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.010_bib0010","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2026.04.010_bib0011","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.4076\/1757-1626-2-8951","article-title":"Adrenocortical carcinoma secreting cortisol, androgens and aldosterone: a case report","volume":"2","author":"Peppa","year":"2009","journal-title":"Cases J"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0012","doi-asserted-by":"crossref","first-page":"bvae199","DOI":"10.1210\/jendso\/bvae199","article-title":"High diagnostic accuracy of arterial phase CT in differentiating pheochromocytoma in good\/poor washout adrenal masses","volume":"9","author":"Phadte","year":"2024","journal-title":"J Endocr Soc"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.010_bib0013","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3390\/diagnostics12092171","article-title":"Adrenal lesions: a review of imaging","volume":"12","author":"Bracci","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.010_bib0014","first-page":"1317","article-title":"Extensive personal experience: adrenocortical tumors","volume":"82","author":"Latronico","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.010_bib0015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jamcollsurg.2005.11.005","article-title":"Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy?","volume":"202","author":"Sturgeon","year":"2006","journal-title":"J Am Coll Surg"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.010_bib0016","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S2213-8587(20)30218-7","article-title":"Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study","volume":"8","author":"Bancos","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.crad.2011.03.023","article-title":"CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies","volume":"67","author":"Zhang","year":"2012","journal-title":"Clin Radiol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.010_bib0018","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/EJE-18-0782","article-title":"Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma","volume":"180","author":"Schweitzer","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.surg.2023.04.070","article-title":"The effect of hormonal secretion on survival in adrenocortical carcinoma: a multi-center study","volume":"175","author":"Sada","year":"2024","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0020","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"189","author":"Fassnacht","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.010_bib0021","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1530\/EJE-10-1147","article-title":"AME position statement on adrenal incidentaloma","volume":"164","author":"Terzolo","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.010_bib0022","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/EJE-16-0297","article-title":"Diagnosis of endocrine disease: the diagnostic performance of adrenal biopsy: a systematic review and meta-analysis","volume":"175","author":"Bancos","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.010_bib0023","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.humpath.2015.08.012","article-title":"Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases","volume":"46","author":"Duregon","year":"2015","journal-title":"Hum Pathol"},{"issue":"50","key":"10.1016\/j.urolonc.2026.04.010_bib0024","first-page":"885","article-title":"Deficits in the management of patients with adrenocortical carcinoma in Germany","volume":"107","author":"Johanssen","year":"2010","journal-title":"Dtsch Arzteblatt Int"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.010_bib0025","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1210\/jc.2010-0653","article-title":"High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors","volume":"95","author":"Sbiera","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.010_bib0026","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000478-198403000-00001","article-title":"Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors","volume":"8","author":"Weiss","year":"1984","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.010_bib0027","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12672-011-0088-0","article-title":"The Weiss score and beyond\u2013histopathology for adrenocortical carcinoma","volume":"2","author":"Papotti","year":"2011","journal-title":"Horm Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.010_bib0028","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/1097-0142(19850215)55:4<766::AID-CNCR2820550414>3.0.CO;2-7","article-title":"Morphologic characteristics of benign and malignant adrenocortical tumors","volume":"55","author":"van Slooten","year":"1985","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.010_bib0029","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/00000478-200212000-00009","article-title":"Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors","volume":"26","author":"Aubert","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2026.04.010_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2016.09.035","article-title":"Validation of the prognostic role of the \u201cHelsinki Score\u201d in 225 cases of adrenocortical carcinoma","volume":"62","author":"Duregon","year":"2017","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.010_bib0031","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/PAS.0b013e31828d387b","article-title":"The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases","volume":"37","author":"Duregon","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.010_bib0032","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.010_bib0033","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/cancers14112721","article-title":"Targeted therapy for adrenocortical carcinoma: a genomic-based search for available and emerging options","volume":"14","author":"Hescheler","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.010_bib0034","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.010_bib0035","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1245\/s10434-020-09562-8","article-title":"Cumulative GRAS score as a predictor of survival after resection for adrenocortical carcinoma: analysis from the U.S. adrenocortical carcinoma database","volume":"28","author":"Baechle","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0036","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1530\/EJE-21-0510","article-title":"S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study","volume":"186","author":"Elhassan","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.010_bib0037","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.surg.2012.08.024","article-title":"Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy","volume":"152","author":"Miller","year":"2012","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.010_bib0038","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.amjsurg.2021.10.014","article-title":"Informing therapeutic lymphadenectomy: location of regional metastatic lymph nodes in adrenocortical carcinoma","volume":"223","author":"Sada","year":"2022","journal-title":"Am J Surg"},{"key":"10.1016\/j.urolonc.2026.04.010_bib0039","unstructured":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS. European multicenter study on role of lymph node dissection in surgical management of adrenal cortical carcinoma. clinicaltrials.gov; 2023 [cited 2025 Oct 5]. Report No.: NCT05763524. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05763524"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.010_bib0040","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.surg.2005.09.012","article-title":"Laparoscopic resection of adrenal cortical carcinoma: a cautionary note","volume":"138","author":"Gonzalez","year":"2005","journal-title":"Surgery"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.010_bib0041","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1245\/s10434-020-08454-1","article-title":"Minimally invasive versus open adrenalectomy in patients with adrenocortical carcinoma: a meta-analysis","volume":"27","author":"Hu","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.010_bib0042","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.010_bib0043","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.surg.2018.06.045","article-title":"Open adrenalectomy through a makuuchi incision: a single institution\u2019s experience","volume":"164","author":"Ruffolo","year":"2018","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.010_bib0044","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.010_bib0045","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0039-6060(97)90229-4","article-title":"Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma","volume":"122","author":"Bellantone","year":"1997","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0046","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1016\/j.ijrobp.2014.05.1456","article-title":"Comparison of stereotactic body radiation therapy and conventional external beam radiation therapy in renal cell carcinoma","volume":"90","author":"Tinkle","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0047","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1530\/EO-22-0050","article-title":"Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options","volume":"2","author":"Al-Ward","year":"2022","journal-title":"Endocr Oncol"},{"issue":"23","key":"10.1016\/j.urolonc.2026.04.010_bib0048","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.04.010_bib0049","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9362108","article-title":"Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis","volume":"2018","author":"Tang","year":"2018","journal-title":"BioMed Res Int"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.010_bib0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/EJE-18-0923","article-title":"Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence","volume":"180","author":"Calabrese","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.010_bib0051","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/jpm11040269","article-title":"What is the optimal duration of adjuvant mitotane therapy in adrenocortical carcinoma? An unanswered question","volume":"11","author":"Basile","year":"2021","journal-title":"J Pers Med"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.010_bib0052","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant Mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.010_bib0053","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41416-021-01513-8","article-title":"Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study","volume":"125","author":"Kimpel","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0054","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.amjsurg.2020.10.038","article-title":"Analysis of adjuvant chemotherapy in patients undergoing curative-intent resection of localized adrenocortical carcinoma","volume":"222","author":"Al Asadi","year":"2021","journal-title":"Am J Surg"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.010_bib0055","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41416-021-01513-8","article-title":"Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study","volume":"125","author":"Kimpel","year":"2021","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.010_bib0056","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0002-9343(66)90220-8","article-title":"Adrenal cortical carcinoma. Results of treatment with o,p\u2019DDD in 138 patients","volume":"41","author":"Hutter","year":"1966","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0057","first-page":"24","article-title":"Efficacy and safety of adjuvant radiotherapy in primary resected adrenocortical carcinoma\u2013a comparative study","volume":"1","author":"Subramani","year":"2026","journal-title":"J UroOncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0058","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.surg.2018.04.068","article-title":"Longitudinal patterns of recurrence in patients with adrenocortical carcinoma","volume":"165","author":"Glenn","year":"2019","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.010_bib0059","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijrobp.2015.01.007","article-title":"Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma","volume":"92","author":"Sabolch","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.010_bib0060","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1210\/jc.2006-1007","article-title":"Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma","volume":"91","author":"Fassnacht","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.010_bib0061","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/ajco.14137","article-title":"Adjuvant radiotherapy after surgical resection improves local control in adrenocortical carcinoma","volume":"21","author":"Zhu","year":"2025","journal-title":"Asia Pac J Clin Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.010_bib0062","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1210\/jc.2019-00029","article-title":"Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma","volume":"104","author":"Gharzai","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2026.04.010_bib0063","article-title":"Efficacy and safety of adjuvant radiation therapy in localized adrenocortical carcinoma","volume":"14","author":"Wu","year":"2023","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0064","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13014-020-01533-3","article-title":"Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis","volume":"15","author":"Zhu","year":"2020","journal-title":"Radiat Oncol Lond Engl"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0065","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/j.ijrobp.2014.05.1454","article-title":"Toxicity of concurrent radiation therapy with mitotane compared to radiation therapy alone in the adjuvant treatment of adrenocortical carcinoma","volume":"90","author":"Sabolch","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.010_bib0066","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41416-022-02082-0","article-title":"Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma","volume":"128","author":"Kimpel","year":"2023","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.urolonc.2026.04.010_bib0067","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.010_bib0068","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors","volume":"102","author":"Henning","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2026.04.010_bib0069","article-title":"Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma","volume":"7","author":"Lagan\u00e0","year":"2022"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.010_bib0070","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/bjs.10414","article-title":"European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma","volume":"104","author":"Gaujoux","year":"2017","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.010_bib0071","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/cancers16040706","article-title":"The value of local therapies in advanced adrenocortical carcinoma","volume":"16","author":"Kimpel","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2026.04.010_bib0072","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fendo.2011.00027","article-title":"Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells","volume":"2","author":"Kroiss","year":"2011","journal-title":"Front Endocrinol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.010_bib0073","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.010_bib0074","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2026.04.010_bib0075","first-page":"SUN","article-title":"SUN-348 cabozantinib in advanced adrenocortical carcinoma: rationale and protocol of two phase II clinical trials","volume":"3","author":"Kroiss","year":"2019","journal-title":"J Endocr Soc"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.010_bib0076","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1210\/clinem\/dgz318","article-title":"Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib","volume":"105","author":"Kroiss","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.010_bib0077","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/biomedicines9030304","article-title":"Immunotherapy in adrenocortical carcinoma: predictors of response, efficacy, safety, and mechanisms of resistance","volume":"9","author":"Araujo-Castro","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0078","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.010_bib0079","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.010_bib0080","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.010_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101434","article-title":"Next-generation therapies for adrenocortical carcinoma","volume":"34","author":"Altieri","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2026.04.010_bib0082","article-title":"Therapeutic strategies for adrenocortical carcinoma: integrating genomic insights, molecular targeting, and immunotherapy","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2026.04.010_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114088","article-title":"Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma","volume":"205","author":"Scatolini","year":"2024","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.010_bib0084","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926002176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926002176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:07:46Z","timestamp":1778584066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926002176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":84,"alternative-id":["S1078143926002176"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary management of adrenocortical carcinoma: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}